Pharmacists: Drug Design Impacts Efficacy and Approved Use in HER2-Low and HER2-Ultra-Low Breast Cancers.

Pharmacists recently discussed the relationship between drug design and its impact on both the efficacy and approved uses of treatments for HER2-low and HER2-ultra-low breast cancer. They highlighted how specific drug designs can influence which patients benefit from a particular therapy, focusing on the nuances within the HER2-low and HER2-ultra-low categories. The discussion centered on the fact that drug design directly affects a drug’s ability to target and interact with HER2 proteins present on cancer cells. Variations in the level of HER2 expression, such as those seen in HER2-low versus HER2-ultra-low breast cancers, can significantly alter a drug’s effectiveness. Therefore, the design of a drug has a great effect on not only how well it works, but also on determining which specific types of breast cancer it is ultimately indicated to treat.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Author

Mark Chiang